News from vanda pharmaceuticals inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

( NASDAQ-NMS:VNDA)

Feb 10, 2016, 16:01 ET

Vanda Pharmaceuticals Reports Fourth Quarter 2015 and Full Year 2015 Financial Results

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial and operational results for the fourth quarter and full year ended...

Feb 01, 2016, 16:30 ET

Vanda Pharmaceuticals to Participate in the Canaccord Genuity Rare Disease, Biopharma One-on-One Day

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of novel...

Jan 22, 2016, 09:20 ET

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2015 Financial Results on February 10, 2016

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it will release results for the fourth quarter of 2015 on Wednesday, February 10,...

Jan 11, 2016, 06:55 ET

Vanda Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2015 Results and 2016 Financial Guidance

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of novel...

Dec 22, 2015, 16:30 ET

European Medicines Agency Accepts Fanaptum® (iloperidone) Marketing Authorization Application for the Treatment of Schizophrenia in Adults

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that its Marketing Authorization Application (MAA) for oral Fanaptum®...

Dec 18, 2015, 07:00 ET

Kenneth Bate Joins the Board of Directors of Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), announced today that Kenneth Bate, an independent biotechnology industry consultant, has joined...

Dec 17, 2015, 16:01 ET

Vanda Pharmaceuticals appoints Gian Piero Reverberi as Acting Chief Commercial Officer

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it has appointed Gian Piero Reverberi to the role of Senior Vice President,...

Nov 12, 2015, 18:00 ET

Vanda Pharmaceuticals Announces Participation at Upcoming Investor Conferences

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products...

Nov 04, 2015, 21:20 ET

Vanda Pharmaceuticals to Participate in the Citi 2015 Global Healthcare 1x1 Conference

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the...

Nov 03, 2015, 16:01 ET

Vanda Pharmaceuticals Reports Third Quarter 2015 Financial Results

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial and operational results for the third quarter ended September 30,...

Oct 15, 2015, 17:00 ET

Vanda Pharmaceuticals to Announce Third Quarter 2015 Financial Results on November 3, 2015

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it will release results for the third quarter of 2015 on Tuesday, November...

Oct 14, 2015, 18:00 ET

Vanda Announces Listing of a New Fanapt® Patent in the FDA Orange Book

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that a Fanapt® patent, number 9,157,121 ('121 patent), is now listed in the...

Sep 23, 2015, 16:30 ET

Vanda Announces Listing of a New Fanapt® Patent in the FDA Orange Book

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that a Fanapt® patent, number 9,138,432 ('432 patent), is now listed in...

Sep 15, 2015, 07:00 ET

Vanda Announces FDA Has Accepted for Review the Fanapt® Supplemental New Drug Application for Maintenance Treatment of Schizophrenia in Adults

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review...

Sep 14, 2015, 07:00 ET

Vanda Pharmaceuticals Announces the Appointment of General Counsel

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it has named Richard Gulino as Vanda's Senior Vice President, General...

Sep 10, 2015, 07:30 ET

Vanda Announces Favorable Markman Ruling in Fanapt® Patent Infringement Litigation

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that a favorable Markman ruling has been issued by the United States...

Sep 08, 2015, 07:00 ET

Vanda Pharmaceuticals Announces the Appointment of European General Manager

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it has named Gian Piero Reverberi as Vanda's Senior Vice President, European...

Aug 10, 2015, 07:00 ET

Vanda Pharmaceuticals to Present at the Canaccord Genuity Annual Growth Conference

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the...

Aug 05, 2015, 07:00 ET

HETLIOZ® (tasimelteon) Phase III SET and RESET Trial Results Published in The Lancet

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced publication of pivotal trial results related to patient entrainment in the...

Aug 03, 2015, 07:00 ET

Vanda Announces Listing of Four New Fanapt® Patents in the FDA Orange Book

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that four new Fanapt® patents are now listed in the U.S. Food and Drug...